Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Latest COVID-19 Developments – A New Treatment Protocol, Falling Mortality, Unexpected Viral Load, and No Benefit From Early Plaquenil Use

Latest COVID-19 Developments – A New Treatment Protocol, Falling Mortality, Unexpected Viral Load, and No Benefit From Early Plaquenil Use

The COVID-19 pandemic, caused by the novel coronavirus, remains active worldwide, and the number of new cases detected each day continues to rise. Meanwhile, noteworthy scientific developments concerning COVID-19 emerge daily. Let us examine these latest developments together.

A Treatment Protocol Too Good to Be True?

There is still no globally accepted, approved treatment or drug for COVID-19. At present, COVID-19 treatment continues through supportive drugs, procedures, and clinical trials. The scientific community is making a major effort to develop a new treatment protocol. Dr. Joseph Varon and a team of other physicians working in the United States redeveloped the MATH+ model, used to treat sepsis in intensive care, for use in COVID-19. An acronym for methylprednisolone, ascorbic acid, thiamine, and heparin, the MATH+ protocol was designed to be personalized for each patient. The formula consists of safe, inexpensive, readily accessible drugs given "permission to be tested" in COVID-19 by the United States Food and Drug Administration (FDA), and was claimed to be effective in patients receiving it. The protocol, administered every 6 hours, was reported to lower mortality and reduce the need for ventilators.

Although disagreements and debate continue about certain components of the protocol, the main issue dividing the scientific community is the lack of randomized trial data (with patients selected at random). In other words, these seemingly positive findings are not the result of a comprehensive clinical trial. However, Dr. Varon, who helped develop the protocol, counters these criticisms by saying: "We are in a war right now, and the number of people we lose increases every day. This is not the time to consider the criticisms. I am certain the protocol will save lives". Although no scientific paper has been published on the MATH+ protocol, which is still in development, its positive features described above continue to spread widely through unofficial channels and the internet.

- Related topic: Is high-dose vitamin C effective in treating COVID-19 patients in intensive care?

Mortality Rates in Intensive Care Units Are Falling

Mortality rates were particularly high in the earliest days of the pandemic. However, a systematic review and meta-analysis of 24 studies across three continents, involving 10,150 patients, found that in intensive care overall COVID-19 mortality fell from 60% in March to 42% in May. The researchers state that this was not because the virus had become less virulent (less lethal), emphasizing instead that growing knowledge and experience with COVID-19 affected survival. Despite the decline, they note that the rate remains twice the mortality observed in other viral pneumonias requiring intensive care. This shows the need for further research and a valid treatment.

The Precautions We Take Could Save Us

A simulation by the University of Washington's Institute for Health Metrics and Evaluation (IHME) found that COVID-19 deaths in the United States could reach 224,000 by 1 November, an increase of 16,000 over previous estimates. An IHME statement said the figure could be reduced by approximately 40,000 if everyone wore masks everywhere outside the home. These studies once again reveal the importance of preventive measures.

Unexpected Viral Load

New research found that people with higher COVID-19 viral loads had less need for hospitalization—at first glance, a surprising finding. Samples were taken to measure viral load (the amount of virus in the sample) in a study of 205 adults diagnosed with COVID-19 at the emergency department of New York University Langone Medical Center. Dr. Paolo Cotzia, a member of the research team, said: "We believe viral load indicates the time of infection onset. Patients with severe symptoms who needed hospitalization had lower viral loads. However, samples were collected later in the course of the illness." This new information could be used to monitor patients and help determine treatment methods.

Early Hydroxychloroquine (the Antimalarial Plaquenil) Treatment Has No Benefit

In patients with mild COVID-19 symptoms who had not been hospitalized, a randomized controlled trial of the antimalarial drug hydroxychloroquine (with patients enrolled at random) showed no benefit from the drug. Although symptoms lasting 14 days were observed in approximately 24% of hydroxychloroquine-treated patients versus 30% in the untreated group, the difference was not statistically significant. Another study reported no effect in approximately 300 nonhospitalized patients in Spain with symptoms lasting less than 5 days. A study testing hydroxychloroquine in more than 4500 hospitalized patients in the United Kingdom found that it did not lower mortality but was associated with longer hospital stays and more deaths or need for ventilation. Together, these studies provide strong evidence that hydroxychloroquine offers no benefit in patients with mild symptoms.

No Need to Repeat COVID-19 Diagnostic Tests

The United States Centers for Disease Control and Prevention (CDC) maintains that people infected with SARS-CoV-2 (the novel coronavirus) whose symptoms have resolved do not need repeated diagnostic tests, and guidance is being prepared on this.

Dr. Admiral Brett P. Giroir said: "We know that if 10 days have passed since symptoms began and you have had no symptoms for at least 3 days, the risk of passing the disease to another person is considered to have ended. Some people are being tested 3 or 6 times, but this is unnecessary, at least for people isolating at home". Dr. Giroir, however, recommends repeat testing for critically ill patients or people with an inadequate immune system.

Will Telemedicine (Remote Healthcare) Become Permanent?

Particularly during the pandemic, telemedicine (remote consultation) has come to the forefront worldwide, with patients choosing telephone or video consultations. United States representatives aim to make permanent changes eliminating geographic restrictions on its use, making remote consultations a permanent legal service even in rural health clinics. The issue is also being discussed extensively in Turkey, where some private hospitals have begun offering it. However, legal regulations governing telemedicine are urgently needed.

With Respect to Our Healthcare Workers...

Throughout this difficult period, healthcare workers have been fighting a serious battle under extremely difficult conditions, risking their own lives. Sadly, more than 1700 healthcare workers worldwide have lost their lives during this time. We respectfully remember all the healthcare workers we have lost.

Scientists continue working to resolve this situation as quickly as possible. It bears repeating that our greatest role during this time is to maintain social distancing, take care to wear masks in all settings outside the home, and wash our hands.

*

- ALL OUR CORONAVIRUS ARTICLES 

*

Sources

1. COVID-19 Update: Unexpected Viral Load, Early HCQ No Help - Medscape - Jul 17, 2020.

2. COVID-19 Update: Treatment Protocol,ICU Mortality - Medscape - Jul 16, 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Latest COVID-19 Developments – A New Treatment Protocol, Falling Mortality, Unexpected Viral Load, and No Benefit From Early Plaquenil Use

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy